Prevention versus intervention of type 1 diabetes

Clinical Immunology

Volumn 149, Issue 3, 2013, Pages 332-338

  Brooks Worrell, Barbara ^a,b   Palmer, Jerry P ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Intervention; Islet autoimmunity; Prediction; Prevention; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ABATACEPT; ALUMINUM POTASSIUM SULFATE; BOVINE INSULIN; C PEPTIDE; CD3 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUTAMATE DECARBOXYLASE; GLUTEN; INSULIN; INSULIN DERIVATIVE; RITUXIMAB; TEPLIZUMAB; THYMOCYTE ANTIBODY;

ARTIFICIAL MILK; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DESTRUCTION; CELL FUNCTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE COURSE; DOWN REGULATION; DRUG EFFICACY; GENETIC RISK; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RELEASE; INSULIN TREATMENT; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; UNSPECIFIED SIDE EFFECT; VACCINATION;

INTERVENTION; ISLET AUTOIMMUNITY; PREDICTION; PREVENTION; TYPE 1 DIABETES; TYPE 2 DIABETES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD3; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; GLUTAMATE DECARBOXYLASE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INSULIN; INSULIN-SECRETING CELLS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84887016461     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.05.018     Document Type: Review

References (54)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
2. Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta.
3. Yoon J.W., Jun H.S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann. N. Y. Acad Sci. 2001, 928:200-211.
4. Lampeter E.F., Homberg M., Quabeck K., Schaefer U.W., Wernet P., Bertrams J., Grosse-Wilde H., Gries F.A., Kolb H. Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993, 341:1243-1244.
5. Skyler J.S. Primary and secondary prevention of type 1 diabetes. Diabet. Med. 2013, 30:161-169.
6. Achenbach P., Bonifacio E., Koczwara K., Ziegler A.G. Natural history of type 1 diabetes. Diabetes 2005, 54:S25-S31.
7. Roll U., Ziegler A.G. Combined antibody screening for improved prediction of IDDM-modern strategies. Exp. Clin. Endocrinol. Diabetes 1997, 105:1-14.
8. Bingley P.J., Christie M.R., Bonifacio E., Bonfanti R., Shattock M., Fonte M.T., Bottazzo G.F., Gale E.A.M. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody positive relatives. Diabetes 1996, 43:1304-1310.
9. Verge C.F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R.A., Chase H.P., Eisenbarth G.S. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bcd/Ia-2 autoantibodies. Diabetes 1996, 45:926-933.
10. Ziegler A.G., Hummel M., Schenkelr M., Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes; the 2-year analysis of the German BABYDIAB Study. Diabetes 1999, 48:460-468.
11. Bendelac A., Carnaud C., Boitard C., Bach J.F. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt2+ T cells. J. Exp. Med. 1987, 166:823-832.
12. Miller B.J., Appel M.C., O'Neil J.J., Wicker L.S. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J. Immunol. 1988, 140:52-58.
13. In't Veld P., Lievens D., De Grijse J., Loing Z., Van der Auwewra B., Pipeleers-Marichal M., Gorus F., Pipeleers D. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 2007, 56:2400-2404.
14. Van Belle T.L., Coppieters K.T., Von Herrath M.G. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 2011, 91:79-118.
15. TRIGR Study Group Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr. Diabetes 2007, 8:117-137.
16. Knip M., Virtanen S.M., Seppa K., Llonen J., Savilahti E., Vaarala O., Reunanen A., teramo K., Hamalainen A.M., Paronen J., Dosch H.M., Hakulinen T., Akerblom H.K., Finnish TRIGR Study Group Dietary intervention in infancy and later signs of beta-cell autoimmunity. NEJM 2010, 363:1900-1908.
17. Vaarala O., llonen J., Ruohtula T., Pesola J., Virtanen S.M., Harkonen T., Koski M., Kallioinen H., Tossavainen O., Poussa T., Jarvenpaa A.L., Komulainen J., Lounamaa R., Akerblom H.K., Knip M. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch. Pediatr. Adolesc. Med. 2012, 166:608-614.
18. Hummel S., Pfluger M., Hummel M., Bonifacio E., Ziegler A.G. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 2011, 34:1301-1305.
19. Achenbach P., Barker J., Bonifacio E., Pre-POINT study group Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr. Diabetes Rep. 2008, 8:87-93.
20. Gale E.A., Bingley P.J., Emmett C.L., Collier T., European Nicotinamide Diabetes Intervention Trial (ENDIT) Group European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363:925-931.
21. Schatz D.A., Bingley P.J. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J. Pediatr. Endocrinol. Metab. 2001, 14:S619-S622.
22. DPT-1 Study Group The Diabetes Prevention Trial-Type 1 diabetes (DPT-1): implementation of screening and staging of relatives. Transplant Proced. 1995, 27:3377.
23. Skyler J.S., Krischer J.P., Wolfsdorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2005, 28:1068-1076.
24. Herold K.C., Bluestone J.A., Montag A.G., et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992, 41:385-391.
25. Greenbaum C.J., Cuthbertson D., Krischer JP, the DPT-1 Study Group Type 1 diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 2001, 50:470-476.
26. Assan R., Feutren G., Debray-Sachs M., Quiniou-Debrie M.C., Laborie C. Metabolic and immunological effects of cyclosporine in recently diagnosed type 1 diabetes mellitus. Lancet 1985, 1:67-71.
27. Stiller C., et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984, 223:1362-1367.
28. Bougneres P.F., et al. Limited duration of remission of insulin dependency in children with recent overt type 1 diabetes treated with low-dose cyclosporin. Diabetes 1990, 39:1264-1272.
29. Staeva-Vieira T., Peakman M., von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type1 diabetes. Clin. Exp. Immunol. 2007, 148:17-31.
30. Orban T., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., Gottlieb P.A., Greenbaum C.J., Marks J.B., Monzavi R., Moran A., Raskin P., Rodriguez H., Russell W.E., Schatz D., Wherrett D., Wilson D.M., Krischer J.P., Skyler J.S., Type 1 Diabetes TrialNet Abatacept Study Group Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 378:412-419.
31. Mastrandrea L., Yu J., Behrens T., Buchlis J., Albini C., Fourtner S., Quattrin T. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009, 32:1244-1249.
32. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
33. Haller M.J., Schatz D.A. CD3-antibody therapy in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 2005, 353:2086-2087.
34. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., Gorus F., Goldman M., Walter M., Candon S., Schandene L., Crenier L., De B.V., Seigneurin J.M., De P.P., Pierard D., Weets I., Rebello P., Bird P., Berrie E., Frewin M., Waldmann H., Bach J.F., Pipeleers D., Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 2005, 352:2598-2608.
35. Sherry N., Hagopian W., Ludvigsson J., et al. Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized placebo-controlled trial. Lancet 2011, 378:487-497.
36. SOURCE Tolerx, Inc. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in type 1 diabetes did not meet its primary endpoint. PRNewswire, March 11, 2011.
37. Malone D.G. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 2012, 366:2008-2016.
38. Cooper N., Arnold D.M. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol. 2010, 149:3-13.
39. Herold K.C., Pescovitz M.D., McGee P., Krause-Steinrauf H., et al. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (Rituximab) therapy in type 1 diabetes. J. Immunol. 2011, 187:1998-2005.
40. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., Gottlieb P.A., Marks J.B., McGee P.F., Moran A.M., et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 2009, 361:2143-2152.
41. Voltareli J.C., Couri C.E.B., Stracieri A.B.P.L., Oliveira M.C., Moraes D.A., Pieroni F., Coutinho M., Malmegrim K.C.R., Foss-Freitas M.C., Simoes B.P., Foss M.C., Squiers E., Burt R.K. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007, 297:1568-1576.
42. Couri C.E.B., Oliveira M.C.B., Stracieri A.B.P.L., Moraes D.A., Pieroni F., Barros G.M.N., Madeira M.I.A., Malmegrim K.C.R., Fos-Freitas M.C., Simoes B.P., Martinez E.Z., Foss M.C., Burt R.K., Voltarelli J.C. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301:1573-1579.
43. Leal A.M.O., Oliveira M.C., Couri C.E.B., Moraes D.A., Stracieri A.B.P.L., Pieroni F., Soares R.D.A., Garros G.N., Sioes B.P., Foss M.C., Voltarelli J.C. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT. Bone Marrow Transplant. 2012, 47:467-468.
44. Wherrett D.K., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomized double-blind trial. Lancet 2011, 378:319-327.
45. Ludvigsson J., Krisky D., Casas R., Battelino T., Castano L., Greening J., Kordonouri O., Otonkoski T., Pozzilli P., Robert J.J., Veeze H.J., Palmer J.P. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. NEJM 2012, 366:433-442.
46. Gianani R., CampbellThompson M., Sarkar S.A., Wasserfall C., Pugliese A., et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010, 53:690-698.
47. Rowe P.A., Campbell-Thompson M.L., Schatz D.A., Atkinson M.A. The pancreas in human type 1 diabetes. Semin. Immunopathol. 2011, 33:29-43.
48. Campbell-thompson M., Wasserfall C., Kaddis J., Albanese-O'Neill A., Staeva T., Nierras C., et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab. Res. Rev. 2012, 28:608-617.
49. Dassau E., Zisser H., Harvey R.A., Percival M.W., Grosman B., Bevier W., Atlas E., Miller S., Nimri R., Joanovic L., Doyle F.J. Clinical evaluation of a personalized artificial pancreas. Diabetes Care 2013, 36:801-809.
50. Lehmann P.V., et al. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992, 358:155-157.
51. Brooks-Worrell B., Gersuk V.H., Greenbaum G., Palmer J.P. Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. J. Immunol. 2001, 166:5265-5270.
52. Turk M.J., Wolchok J.D., Guevara-Patino J.A., Goldberg S.M., Houghton A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 2002, 188:122-135.
53. Ngiow S.F., von Scheidt B., Moller A., Smyth M.J., Teng M.W.L. The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. OncoImmunology 2013, 1-10. (e23036).
54. Kottke T., Pulido J., Thompson J., Sanchez-Perez L., Chong H., Calderwood S.K., Selby P., Harrington K., Strome S.E., Melcher A., Vile R.G. Antitumor Immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res. 2009, 69:7767-7774.